Compare Citius Pharmaceuticals Inc (CTXR) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs JPMorgan Equity Premium Income ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.55B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 3344.3× Citius Pharmaceuticals Inc's market cap, and JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and JPMorgan Equity Premium Income ETF for 57 Days on average.
| CTXR | JEPI | |
|---|---|---|
Market Cap | $13.62M | $45.55B |
Volume | 132,438 | 3,820,809 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $59.88 |
52-Week Low | $0.48 | $55.29 |
Typical Hold Time | 17 Days | 57 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
JEPI trades at $56.67, up 0.39% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF shows consistent dividend distributions with recent payments of $0.37 in August and July 2026. Media coverage focuses on income strategies and tax implications, with Seeking Alpha highlighting JEPI's role as a hedge against tech-led market declines.
The outlook remains income-focused with steady monthly distributions, though covered-call strategies may limit upside during rallies. Key risks include interest rate sensitivity and tax inefficiencies, while institutional interest continues with Envestnet increasing its stake by 20.9% in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
